Pages that link to "Q34568280"
Jump to navigation
Jump to search
The following pages link to New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection (Q34568280):
Displaying 35 items.
- Microbicides: topical prevention against HIV (Q26999403) (← links)
- Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex (Q27679932) (← links)
- An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors (Q28477736) (← links)
- A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity. (Q30654651) (← links)
- The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1 (Q33725916) (← links)
- Pharmacological characterization of a small‐molecule agonist for the chemokine receptor CXCR3 (Q34007358) (← links)
- Constitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion (Q34565057) (← links)
- Enhanced replication of R5 HIV-1 isolates in vitro by a small-molecule reagent targeting HIV-1 protease (Q34627166) (← links)
- Protein kinase Ctheta is a specific target for inhibition of the HIV type 1 replication in CD4+ T lymphocytes. (Q35144874) (← links)
- Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5). (Q35312348) (← links)
- HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug (Q35665842) (← links)
- Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors (Q35689392) (← links)
- Impaired NK Cell Activation and Chemotaxis toward Dendritic Cells Exposed to Complement-Opsonized HIV-1. (Q35925669) (← links)
- Analysis of Chemokine Receptor Trafficking by Site-Specific Biotinylation (Q36054360) (← links)
- CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity (Q36246273) (← links)
- Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues (Q36756170) (← links)
- Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants. (Q36911645) (← links)
- HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines (Q36915528) (← links)
- Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits (Q37025888) (← links)
- Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5. (Q37502946) (← links)
- Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors (Q38076139) (← links)
- Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. (Q38415577) (← links)
- Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor (Q38703060) (← links)
- On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets (Q38710840) (← links)
- Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5. (Q38769265) (← links)
- The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. (Q38937068) (← links)
- Identification of potential CCR5 inhibitors through pharmacophore-based virtual screening, molecular dynamics simulation and binding free energy analysis (Q39314390) (← links)
- Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. (Q39523186) (← links)
- Preclinical discovery and development of maraviroc for the treatment of HIV. (Q39556338) (← links)
- Incorporating the type and direction information in predicting novel regulatory interactions between HIV-1 and human proteins using a biclustering approach. (Q41951886) (← links)
- A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands (Q42003151) (← links)
- Development of peptide inhibitors of HIV transmission. (Q55317261) (← links)
- CCR5 structural plasticity shapes HIV-1 phenotypic properties (Q60046351) (← links)
- Integrated Computational Approaches and Tools forAllosteric Drug Discovery (Q89510669) (← links)
- Inhibitory effect of PIK-24 on respiratory syncytial virus entry by blocking phosphatidylinositol-3 kinase signaling (Q97902342) (← links)